Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
Middle East & Africa Blood Transfusion Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments & Kits and Reagents), Application (Blood Grouping and Disease Screening), and End User (Hospitals, Diagnostic Laboratories, Blood Banks, and Plasma Fractionation Companies)
- Report Code : BMIRE00027421
- Pages : 131
The MEA blood transfusion diagnostics market is expected to grow from US$ 151.99 million in 2022 to US$ 199.02 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028.
Technological Developments in Blood Transfusion Diagnostics to Brings New Trends to Market
Blood transfusion diagnostics are usually deployed during long-hour surgeries, such as kidney transplants, and in cases of emergencies. These surgeries are associated with the chances of excessive blood loss, which makes it difficult to make up for the blood loss with new blood, especially in the case of rare blood groups. Due to the ample demand, key players in the blood transfusion diagnostics market are offering advanced and fully automated blood transfusion diagnostics that reduce human interventions. For instance, in April 2019, BD launched its BD BACTEC quality control media to help identify contaminated platelet units during transfusions. Many companies employ strategic activities, such as acquisitions and partnerships, to capture better shares in the market. In December 2019, Getinge purchased Applikon Biotechnology, a leader in the development and supply of innovative bioreactor systems suitable for all scales, ranging from laboratory to industrial. In October 2019, Medtronic acquired AV Medical Technologies. Such advancements are likely to bring new trends in the blood transfusion diagnostics market in the coming years.
Market Overview
In 2021, South Africa held the largest share of the blood transfusion diagnostics market in the MEA. The country records the increasingly high incidence of various chronic diseases, such as diabetes, cancer, cardiovascular, and infectious diseases, requiring surgical procedures as a treatment. Also, healthcare facilities in South Africa are developing and adopting the latest technologies to offer better treatments. An article titled “Improving Sepsis Care in Africa, 2021” estimated that ~85% of sepsis cases occur in low and middle-income countries, with the highest burden in Africa. In addition, children (especially newborns), pregnant women, and elderly people are the most affected population. In Africa, ~17 million cases and 3.5 million deaths occurred in 2017 due to sepsis. Further, the increasing cases of sickle cell anemia (SCD) and thalassemia in South Africa are likely to complement the blood transfusion diagnostics market in South Africa. According to data published in Pan African Medical Journal, the World Health Organization (WHO) estimates ~50 million people with sickle cell trait globally, with the cases reaching 38 million in sub-Saharan Africa; Africa has 500,000 children with sickle cell disease, and 70% die before they turn 5 years of age, due to the lack of adequate care. SCD patients frequently require a blood transfusion, which can be associated with the increased demand for blood transfusion diagnostics in the country.
MEA Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
MEA Blood Transfusion Diagnostics Market Segmentation
The MEA blood transfusion diagnostics market is segmented based on product, application, end user, and country.
Based on product, the MEA blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held the larger market share in 2022. Based on application, the MEA blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held the larger market share in 2022. Based on end user, the MEA blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022. Based on country, the MEA blood transfusion diagnostics market has been categorized into the UAE, Saudi Arabia, South Africa, and Rest of the MEA. Our regional analysis states that South Africa dominated the market in 2022. Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the MEA blood transfusion diagnostics market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Blood Transfusion Diagnostics Market – By Product
1.3.2 MEA Blood Transfusion Diagnostics Market – By Application
1.3.3 MEA Blood Transfusion Diagnostics Market – By End User
1.3.4 MEA Blood Transfusion Diagnostics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Blood Transfusion Diagnostics Market – Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Experts Opinion
5. MEA Blood Transfusion Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rapid Increase in Chronic Diseases
5.1.2 Need for Blood Transfusion due to Rise in Organ Transplants Surgeries
5.2 Market Restraints
5.2.1 Problems Associated with Blood Transfusion Services
5.3 Market Opportunities
5.3.1 Elevated Healthcare Expenditure in Emerging Economies
5.4 Future Trends
5.4.1 Technological Developments in Blood Transfusion Diagnostics
5.5 Impact Analysis
6. Blood Transfusion Diagnostics Market– MEA Analysis
6.1 MEA Blood Transfusion Diagnostics Market Revenue Forecast and Analysis
7. MEA Blood Transfusion Diagnostics Market Analysis – By Product
7.1 Overview
7.2 MEA Blood Transfusion Diagnostics Market Revenue Share, by Product (2021 and 2028)
7.3 Instruments and Kits
7.3.1 Overview
7.3.2 Instruments and Kits: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
7.4 Reagents
7.4.1 Overview
7.4.2 Reagents: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
8. MEA Blood Transfusion Diagnostics Market Analysis – By Application
8.1 Overview
8.2 MEA Blood Transfusion Diagnostics Market Revenue Share, by Application (2021 and 2028)
8.3 Disease Screening
8.3.1 Overview
8.3.2 Disease Screening: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
8.4 Blood Grouping
8.4.1 Overview
8.4.2 Blood Grouping: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9. MEA Blood Transfusion Diagnostics Market Analysis – By End User
9.1 Overview
9.2 MEA Blood Transfusion Diagnostics Market Share, by End User, 2021 and 2028, (%)
9.3 Blood Banks
9.3.1 Overview
9.3.2 Blood Banks: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
9.4 Hospitals
9.4.1 Overview
9.4.2 Hospitals: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
9.6 Plasma Fractionation Companies
9.6.1 Overview
9.6.2 Plasma Fractionation Companies: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
10. MEA Blood Transfusion Diagnostics Market Analysis – Country Analysis
10.1 Overview
10.1.2 MEA: Blood Transfusion Diagnostics Market, by Country, 2021 & 2028 (%)
10.1.2.1 South Africa: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 Overview
10.1.2.1.2 South Africa Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.3 South Africa: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
10.1.2.1.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Application (US$ Million)
10.1.2.1.5 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By End User (US$ Million)
10.1.2.2 Saudi Arabia: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Overview
10.1.2.2.2 Saudi Arabia Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.3 Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
10.1.2.2.4 Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecasts To 2028, By Application (US$ Million)
10.1.2.2.5 Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecasts To 2028, By End User (US$ Million)
10.1.2.3 UAE: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 Overview
10.1.2.3.2 UAE: Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.3 UAE: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
10.1.2.3.4 UAE: Blood Transfusion Diagnostics Market Revenue and Forecasts To 2028, By Application (US$ Million)
10.1.2.3.5 UAE: Blood Transfusion Diagnostics Market Revenue and Forecasts To 2028, By End User (US$ Million)
10.1.2.4 Rest of the MEA: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.1 Overview
10.1.2.4.2 Rest of the MEA Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.3 Rest of MEA: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
10.1.2.4.4 Rest of MEA: Metabolomics Market Revenue and Forecasts To 2028, By Application (US$ Million)
10.1.2.4.5 Rest of MEA: Metabolomics Market Revenue and Forecasts To 2028, By End User (US$ Million)
11. Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.2.1 Overview
11.3 Organic Growth Strategies
11.3.1 Overview
12. Company Profiles
12.1 Grifols, S.A.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Immucor, Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bio-Rad Laboratories, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Abbott
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Ortho Clinical Diagnostics (QuidelOrtho Corporation)
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 DiaSorin S.p.A.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Quotient Limited
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 BAG Diagnostics GmbH
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. MEA Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (US$ Mn)
Table 2. South Africa Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
Table 3. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 4. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By End User (US$ Million)
Table 5. Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
Table 6. Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 7. Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By End User (US$ Million)
Table 8. UAE: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
Table 9. UAE: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 10. UAE: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By End User (US$ Million)
Table 11. Rest of MEA: Blood Transfusion Diagnostics Market Revenue and Forecasts to 2028, By Product (US$ Million)
Table 12. Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 13. Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By End User (US$ Million)
Table 14. Recent Inorganic Growth Strategies
Table 15. Recent Organic Growth Strategies
Table 16. Glossary of Terms
LIST OF FIGURES
Figure 1. MEA Blood Transfusion Diagnostics Market Segmentation
Figure 2. MEA Blood Transfusion Diagnostics Market – By Country
Figure 3. MEA Blood Transfusion Diagnostics Market Overview
Figure 4. MEA Blood Transfusion Diagnostics Market, By Product
Figure 5. MEA Blood Transfusion Diagnostics Market, By Country
Figure 6. MEA: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis: MEA Blood Transfusion Diagnostics Market
Figure 9. MEA Blood Transfusion Diagnostics Market– Revenue Forecast and Analysis
Figure 10. MEA Blood Transfusion Diagnostics Market Revenue Share, by Product (2021 and 2028)
Figure 11. MEA Instruments and Kits: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 12. MEA Reagents: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 13. MEA Blood Transfusion Diagnostics Market Revenue Share, by Application (2021 and 2028)
Figure 14. MEA Disease Screening: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 15. MEA Blood Grouping: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 16. MEA Blood Transfusion Diagnostics Market Share, by End User, 2021 and 2028 (%)
Figure 17. MEA Blood Banks: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
Figure 18. MEA Hospitals: Blood Transfusion Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 19. MEA Diagnostic Laboratories: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
Figure 20. MEA Plasma Fractionation Companies: Blood Transfusion Diagnostics Market, Revenue and Forecast to 2028 (US$ Million)
Figure 21. MEA Blood Transfusion Diagnostics Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 22. MEA: Blood Transfusion Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 23. South Africa: Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Figure 24. Saudi Arabia: Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. UAE: Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. Rest of the MEA: Blood Transfusion Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA blood transfusion diagnostics market.
● Highlights key business priorities to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the MEA blood transfusion diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the blood transfusion diagnostics market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – Middle East & Africa Blood Transfusion Diagnostics Market
● Abbott
● BAG Diagnostics GmbH
● Bio-Rad Laboratories, Inc.
● DiaSorin S.p.A.
● F. Hoffmann-La Roche Ltd
● Grifols, S.A.
● Immucor, Inc.
● Ortho Clinical Diagnostics (QuidelOrtho Corporation)
● Quotient Limited
● Thermo Fisher Scientific Inc.
At 4.6% CAGR, the MEA Blood Transfusion Diagnostics Market is speculated to be worth US$ 199.02 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the MEA blood transfusion diagnostics market was valued at US$ 151.99 million in 2022 and is expected to reach US$ 199.02 million by 2028, registering an annual growth rate of 4.6% from 2022 to 2028. Elevated healthcare expenditure in emerging economies and technological developments in blood transfusion diagnostics are the critical factors attributed to the market expansion.
Healthcare budget allocations help countries strengthen the workforces and improve this sector’s productivity, thereby contributing to economic performance. Rapid economic developments have fueled the healthcare expenditure in developing countries, which enables them to establish better medical service infrastructure. Developing countries are significantly focusing on expanding and improving their healthcare facilities and services by leveraging technological advancements. These nations aim to introduce advanced healthcare facilities and services to overcome critical health issues. Several initiatives are likely to provide lucrative opportunities for market players to introduce advanced technologies in blood transfusion diagnostics, which in turn, will add to the growth of the market during the forecast years.
On the contrary, problems associated with blood transfusion services hurdles the growth of MEA blood transfusion diagnostics market.
Based on product, the MEA blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held 67.4% market share in 2022, amassing US$ 102.47 million. It is projected to garner US$ 135.47 million by 2028 to expand at 4.8% CAGR during 2022–2028. Based on application, the MEA blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held 61.3% market share in 2022, amassing US$ 93.17 million. It is projected to garner US$ 122.86 million by 2028 to expand at 4.7% CAGR during 2022–2028. Based on end user, the MEA blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment held 39.7% market share in 2022, amassing US$ 60.32 million. It is projected to garner US$ 81.57 million by 2028 to expand at 5.2% CAGR during 2022–2028. Based on country, the MEA blood transfusion diagnostics market has been categorized into the UAE, Saudi Arabia, South Africa, and rest of MEA. Our regional analysis states that South Africa captured 35.9% market share in 2022. It was assessed at US$ 54.58 million in 2022 and is likely to hit US$ 73.96 million by 2028, exhibiting a CAGR of 5.2% during the forecast period. Key players dominating the MEA blood transfusion diagnostics market are Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. among others.
March 2022, Immucor, a leader in the immunohematology industry, announced that automated monoclonal Jka and Jkb phenotype testing is now available on the NEO Iris/NEO (v2.0). Immucor’s fully automated Jka and Jkb phenotype assay brings ease of use, high sensitivity, and reduced subjectivity for Kidd antigen testing.
In July 2022, Quotient Limited announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the two companies will partner to advance the safety and effectiveness of infectious disease testing by leveraging Quotient’s MosaiQ solution.
Related Reports
- $3,000.00 – $5,000.00
